As­traZeneca’s Imfinzi/treme com­bo strikes out — again — in lung can­cer. Is it time for last rites?

6 years ago
R&D
Pharma

We­bi­nar: Re­al World End­points — the brave new world com­ing in build­ing fran­chise ther­a­pies

6 years ago
FDA+

Pfiz­er Foun­da­tion of­fers $2M in grants to NGOs tack­ling an­timi­cro­bial re­sis­tance; Bio­gen, In­vi­tae join forces to ...

6 years ago
News Briefing

FDA de­ci­sion on Ver­tex's CF triple will come just ahead of planned CEO shake­up

6 years ago
R&D
FDA+

An MIT spin­out kills one of its ‘liv­ing ther­a­peu­tics’ af­ter flunk­ing an ear­ly-stage study — shares rout­ed

6 years ago
R&D

Elan­co to buy Bay­er's an­i­mal health busi­ness for $7.6B, as deal­mak­ing gath­ers steam in the sec­tor

6 years ago
Deals
Pharma

Fresh from $102M haul, IGM Bio pitch­es $100M IPO as it plots first-in-hu­man tri­al of new an­ti­bod­ies

6 years ago
Financing

As­traZeneca's di­a­betes drug Farx­i­ga helps pa­tients with heart dis­ease and with­out di­a­betes in land­mark tri­al

6 years ago
R&D
Pharma

Pay­back? An­a­lysts say Sarep­ta was blind­sided by an FDA re­jec­tion dri­ven by reg­u­la­to­ry re­venge

6 years ago
R&D
FDA+

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

6 years ago
People

No­var­tis spin­off Nabri­va fi­nal­ly scores its first an­tibi­ot­ic ap­proval

6 years ago
R&D
Pharma

Roche raids Eli Lil­ly for its next chief med­ical of­fi­cer as San­dra Horn­ing plans to step down

6 years ago
People

Glen­mark launch­es Re­mogliflozin com­bo in In­dia; Gene­Cen­tric Ther­a­peu­tics buys Se­lect Im­munoGenomics

6 years ago
News Briefing

Af­ter a posse of Wall Street an­a­lysts pre­dict a like­ly new win for Sarep­ta, we're down to the wire on a crit­i­cal FDA ...

6 years ago
R&D

Spring­Works seeks $115M to push Pfiz­er drugs across fin­ish line while Sat­suma sells mi­graine play in $86M IPO

6 years ago
Financing

Mi­nor­i­ty racial groups con­tin­ue to be dis­mal­ly rep­re­sent­ed in can­cer tri­als — study

6 years ago
R&D

Van­da shares slide af­ter FDA spurns their big end­point and re­jects a pitch on jet lag re­lief

6 years ago
R&D

I’m not per­fect: No­var­tis chief Vas Narasimhan al­most apol­o­gizes in the wake of a new cri­sis

6 years ago
Pharma

EMA and FDA his­tor­i­cal­ly agree on just about every new drug ap­proval, but is that slow­ly chang­ing?

6 years ago
FDA+

Health­i­er, longer lifes­pans will be a re­al­i­ty soon­er than you think, Ju­ve­nes­cence promis­es as it clos­es $100M round

6 years ago
Financing

Ab­b­Vie gets its FDA OK for JAK in­hibitor upadac­i­tinib, but don’t look for this one to hit ex­ecs’ lofty ...

6 years ago
R&D

Cel­gene and the sci­en­tist who cham­pi­oned fe­dra­tinib's rise from Sanofi's R&D grave­yard win FDA OK

6 years ago
Pharma
FDA+

ICER blasts FDA, PTC and Sarep­ta for high prices on DMD drugs Em­flaza, Ex­ondys 51

6 years ago
Pharma

The top 10 fran­chise drugs in bio­phar­ma his­to­ry will earn a to­tal of $1.4T (tril­lion) by 2024 — what does that tell ...

6 years ago
Pharma
First page Previous page 921922923924925926927 Next page Last page
A service from the Financial Times